A Phase Ib, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK-0646 in Advanced Non-Small-Cell Lung Cancer.

Merck & Co., Inc. One Merck DriveP.O. Box 100Whitehouse Station, NJ, 08889-0100, U.S.A.0 个研究点目标入组 106 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 106

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Patients must meet all of the following criteria to participate in this study:
•1.Patient has histologically or cytologically documented, unresectable, locally advanced or metastatic Stage IIIb/IV NSCLC.
•2.Patient has measurable disease (at least one measurable primary or other intrathoracic/supraclavicular lesion ≥2 cm).
•3.Patient has archival tumor tissue available (at site or confirmed at an off-site location) prior to drug administration.
•4.Patient has had one or two prior systemic chemotherapy regimens for recurrent or metastatic disease.
•5.(Part I only) Patient meets either of the following criteria:
•a.Female non-smoker with non-squamous histology, who has had one or two prior systemic chemotherapies.
•b.Documented EGFR mutation associated with EGFR inhibitor sensitivity, or EGFR gene amplification, regardless of other demographic or clinical characteristics, who has had no more than two prior systemic chemotherapies.
•6.(Part II only) Patient has accessible tumor(s) and consents to undergo a tumor core needle biopsy.
•7.Patient is male or female, and 18 years of age on the day of signing informed consent.
•8.Patient has a performance status 0-2 on the ECOG Performance Scale.
•9.Patient must have adequate organ function.
•10.Female patient of childbearing potential has a negative serum or urine pregnancy test within 28 days of study enrollment.
•11.Male and female patients agree to use adequate contraception during therapy with erlotinib alone or MK-0646 in combination with erlotinib. Note that simultaneous use of two reliable forms of contraception is recommended for the entire study period and ending 28 days after the last dose of study drug.
•12.Patient, or the patient?s legal representative, has voluntarily agreed to participate by giving written informed consent.

排除标准

•A patient meeting any of the following criteria is not eligible to participate in this study:
•1.Patient who has had chemotherapy within 2 weeks prior to entering the study, or biological therapy such as bevacizumab (Avastin®) within 4 weeks prior to entering the study, or who has not recovered to at least grade 1 or baseline from adverse events due to agents administered prior to entering the study.
•2.Patient who has had radiotherapy to a field that affects the chest or abdomen, or thoracic surgery within the 3 months prior to entering the study.
•3.Patient who has received prior EGFR ? tyrosine kinase inhibitor/anti-EGFR mAb therapy or prior IGF1R ? tyrosine kinase inhibitor/anti-IGF1R mAb therapy.
•4.Patient is currently participating or has participated in a study with an investigational compound or device within 30 days (or 5 half-lives of the investigational compound) of initial dosing with study drug.
•5.Patients with untreated brain metastases or carcinomatous meningitis are excluded. However, patients who have stable CNS metastases for 4 weeks off of corticosteroids, and who are at least 4 weeks from the time of appropriate local therapy for CNS disease are eligible for protocol enrollment.
•6.Patient has known hypersensitivity to the components of study drug or its analogs.
•7.Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient?s participation for the full duration of the study, or is not in the best interest of the patient to participate.
•8.Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
•9.Patient has atelectasis that prevents delineation of primary tumor.
•10.Patient has post-obstructive pneumonia.
•11.Patient has pure bronchoalveolar carcinoma.
•12.Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
•13.Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study.
•14.Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
•15.Patient has active viral hepatitis.
•16.Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician.
•17.Patient is concurrently using growth hormone (GH), or growth hormone inhibitors.
•18.Patient has poorly controlled diabetes mellitus with fasting serum glucose 150 mg/dL at screening visit. This includes patients who are taking steroids that cause fasting serum glucose  150 mg/dL.

研究者

发起方

Merck & Co., Inc. One Merck DriveP.O. Box 100Whitehouse Station, NJ, 08889-0100, U.S.A.

相似试验

已完成

2 期

The safety of Cpn10 in patients with multiple sclerosisNeurological - Multiple sclerosisMultiple Sclerosis

ACTRN12606000037505CBio Limited50

已完成

2 期

A clinical trial to evaluate immunogenicity and safety of Live Varicella vaccine (Oka Strain) in Indian children.

CTRI/2014/03/004445Biomed Private Limited252

已完成

不适用

Phase II Multicenter Clinical Trial to evaluate the immune response generation capacity and the safety of the ALVAC-HIVVCP1452 Vaccine administered alone and in combination with the MN rpg 120 / HIV-1 vaccine in humans from Brazil, Haiti, Peru and Trinidad and Tobago.-B23 Human immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in other conditionsB23

PER-036-01FRED HUTCHINSON CANCER RESEARCH CENTER,

进行中（未招募）

1 期

Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001241-84-GBovartis Pharma Services AG23

进行中（未招募）

1 期

EUCTR2015-001241-84-FRovartis Pharma Services AG23